Newsroom: Latest News
Emmanuel Dulac Appointed as new CEO of Igyxos
Nouzilly, June 20, 2023 – Igyxos, a privately owned biopharmaceutical company developing breakthrough treatments for infertility and dedicated to enhancing patients’ outcomes, is delighted to announce the appointment of Emmanuel Dulac as its new CEO. Emmanuel brings a wealth of experience and expertise to Igyxos, having held numerous leadership positions in the pharmaceutical and biotechnology industry.
Emmanuel's distinguished career spans over 25 years, during which he has successfully led and transformed businesses in the global biotechnology sector. Prior to taking the lead at Igyxos, Emmanuel served as the CEO of Zealand Pharma, CCO of Alnylam and Head of Rare Diseases at Shire, where he played a pivotal role in driving innovation and business growth.
With a strong track record of strategic vision and execution, Emmanuel is poised to guide Igyxos into its next phase of development and expansion. His leadership skills, combined with his deep understanding of biotechnology, make him the ideal choice to lead Igyxos through the evolving challenges and opportunities of the industry.
Commenting on his appointment, Emmanuel said, "I am honored to join Igyxos as its CEO to lead an exceptional team of talented individuals and help advance this promising pipeline for infertile couples looking to build families. Igyxos has a strong reputation in research for delivering innovative solutions, and I look forward to further enhance our reputation in the clinics and drive continued success."
As the new CEO, Emmanuel will focus on accelerating Igyxos's growth trajectory in the clinics, fostering strategic partnerships, and continue to drive innovations across its product portfolio. His global market experience, customer-centric approach and commitment to excellence align perfectly with Igyxos's values and mission.
This announcement follows a series of recent successes for Igyxos lead product IGX12, first in class mAb, showing strong response in both male and female, alone or in combination with FSH and in various animal models. The appointment of Emmanuel Dulac signals Igyxos's determination to build on its momentum and achieve even greater success.
Igyxos is a biotechnology company building on its expertise and experience of his team to provide innovative treatment in the field of infertility. Igyxos is involved in all phases of development, from the discovery of promising targets to the identification of potential active compounds such as small molecules and antibodies. The success of its €7.5 million Series A funding led by Bpifrance, through the FABS funds, alongside with Go Capital Amorçage II and Loire Valley Invest Funds managed by Go Capital and the Emergence Innovation II Fund managed by Sofimac Innovation, will allow Igyxos to develop its lead compound, IGX12 and reach clinical proof of concept. www.igyxos.com.
06 64 28 81 31
06 03 34 75 36